Clinical and pharmacokinetic interactions between methadone and nelfinavir (Nemesia study);Interacciones clínicas y farmacocinéticas entre metadona y nelfinavir (estudio Nemesia)

Medicina Clinica

Volumn 127, Issue 2, 2006, Pages 47-49

  Marco, Andrés ^a   Deig, Elisabet ^b   Cadafalch, Josep ^c   Fuster, Montserrat ^c   Valls, Inmaculada ^a   Pedrol, Enric ^b  

^a Programa VIH/SIDA   (Spain)

^b HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Adverse effects; HIV; Methadone; Nelfinavir; Opiate withdrawal symptoms; Pharmacokinetic studies

Indexed keywords

METHADONE; NELFINAVIR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; QUESTIONNAIRE; SYMPTOMATOLOGY;

EID: 33746123861     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13089988     Document Type: Article

References (10)

1. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother. 2002;36:1598-613.
2. Pérez-Pons JC, Jornet S, Bonet A. Interacciones farmacocinéticas entre metadona y antirretrovirales en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc). 2002;119:224-9.
3. Hsyu Ph, Lillibridge JH, Maroldo L, Weiss R, Kerr M. Pharmacokinetic (PK) and pharmacodinamic (PD) interactions between nelfinavir and metadona [resumen 87]. Actas de 7th Conference on Retroviruses and Opportunistic Infections; 2000, enero 30 a febrero 2; San Francisco.
4. McCance-Katz EF, Farber S, Selwin PA, O'Connor A. Decrease in metadona levels with nelfinavir mesylate. Am J Psychiatry. 2000;157:481.
5. Bradley B, Gossop M, Phillips GT, Legarda JJ. The development of an opiate withdrawal scale (OWS). Br J Addict. 1987;82:1139-42.
6. Beauverie P, Taburet AM, Desalles MC, Furlan V, Touzeau D. Therapeutic drug monitoring of metadona in VIH-patients receiving protease inhibitors. AIDS. 1998;12:2510-1.
7. Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, De Caprariis PJ, et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of metadona. J Clin Pharmacol. 2004;44:293-304.
8. Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry M, et al. Absence of opioid withdrawal symptoms in patients receiving metadona and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis. 2002;34:1143-5.
9. Stevens RC, Rapaport S, Maroldo-Connelly L, Patterson JB, Bertz R. Lack of metadona dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2003;33:650-1.
10. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of metadona: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001;27:153-60.